Literature DB >> 12614874

Prodrugs of biologically active phosphate esters.

Carsten Schultz1.   

Abstract

Bioactivatable protecting groups represent an enormously powerful tool to increase bioavailability or to generally help deliver drugs to cells. This approach is particularly valuable in the case of biologically active phosphates because of the high intrinsic hydrophilicity and the multitude of biological functions phosphate esters exhibit inside cells. Here, the most prominent masking groups used so far are introduced. The stability and toxicology of the resulting prodrugs is discussed. Finally, this review tries to cover briefly some of the work that describes the usefulness and efficiency of the approach in various application areas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614874     DOI: 10.1016/s0968-0896(02)00552-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  50 in total

1.  Rational design, synthesis, and evaluation of new selective inhibitors of microbial class II (zinc dependent) fructose bis-phosphate aldolases.

Authors:  Racha Daher; Mathieu Coinçon; Matthieu Fonvielle; Petra M Gest; Marcelo E Guerin; Mary Jackson; Jurgen Sygusch; Michel Therisod
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

2.  Interaction of nucleic acids with the glycocalyx.

Authors:  Michael J Palte; Ronald T Raines
Journal:  J Am Chem Soc       Date:  2012-03-29       Impact factor: 15.419

3.  Challenges in studying phospholipid signaling.

Authors:  Carsten Schultz
Journal:  Nat Chem Biol       Date:  2010-07       Impact factor: 15.040

4.  Molecular tools for cell and systems biology.

Authors:  Carsten Schultz
Journal:  HFSP J       Date:  2007-11-29

5.  An expanded biological repertoire for Ins(3,4,5,6)P4 through its modulation of ClC-3 function.

Authors:  Jennifer Mitchell; Xueqing Wang; Guangping Zhang; Martina Gentzsch; Deborah J Nelson; Stephen B Shears
Journal:  Curr Biol       Date:  2008-10-28       Impact factor: 10.834

6.  Ribonuclease-Activated Cancer Prodrug.

Authors:  Gregory A Ellis; Nicholas A McGrath; Michael J Palte; Ronald T Raines
Journal:  ACS Med Chem Lett       Date:  2012-02-28       Impact factor: 4.345

7.  Design and synthesis of a reagent for solid-phase incorporation of the phosphothreonine mimetic (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) into peptides in a bio-reversible phosphonyl-bis-pivaloyloxymethyl (POM) prodrug form.

Authors:  Wen-Jian Qian; Terrence R Burke
Journal:  Amino Acids       Date:  2013-08-02       Impact factor: 3.520

8.  Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.

Authors:  Wen-Jian Qian; Jung-Eun Park; Dan Lim; Suk-Youl Park; Ki-Won Lee; Michael B Yaffe; Kyung S Lee; Terrence R Burke
Journal:  Chem Biol       Date:  2013-10-10

9.  Potent inhibitors of a shikimate pathway enzyme from Mycobacterium tuberculosis: combining mechanism- and modeling-based design.

Authors:  Sebastian Reichau; Wanting Jiao; Scott R Walker; Richard D Hutton; Edward N Baker; Emily J Parker
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

10.  Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells.

Authors:  Kerstin Egele; Shayak Samaddar; Nina Schneider; David Thompson; Gerhard Wenz
Journal:  J Mater Chem B       Date:  2018-12-07       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.